Page 1of 59
Title
Clinical Validation of DACP  Digital Design
Protocol Number:
Development Stage of 
Project:
Sponsor Name and 
Address:
Test Product:
Investigator Agreement:CLD523-C 001 / [STUDY_ID_REMOVED]
Development
Alcon Research, Ltd. and i
ts 
affiliates (“Alcon”)
6201 South Freeway
Fort Worth, Texas 76134-2099
DAILIES® AquaComfort Plus® (nelfilcon A) Digital Soft 
Contact Lenses
I have read the clin
ical study described herein, and recognize its 
confidentiality . I agree to conduct this study
 in accordance with 
the ethical principles contained within the Declaration of 
Helsinki, and the described study in compliance with the 
protocol, Good Clinical Practice (GCP), I SO 14155, and all 
applicable regu latory requirements. Additionally , I will comply 
with all procedures for data recording and reporting, will permit 
monitoring, auditin
g, and inspection of my research center, and 
will retain all records until notified by the Study Sponsor.
Principal I nvestigator:
Signature Date
Name and professional 
position:
Address:
Template version 1.0, approved 09JUNE 2017
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018
Page 2of 59
Table of Contents
Table of Contents .......................................................................................................................2
List of T ables ..............................................................................................................................4
List of Figure s
............................................................................................................................5
1
GLOSSAR Y OF TERMS ....................................................................................................6
2LIST OF ACRONYMS AND ABBREVIA TIONS ...........................................................10
3PROT OCOL  SUMMAR Y
.................................................................................................12
4PROT OCOL AMENDMENTS
.........................................................................................20
4.1 Amendments ......................................................................................................21
5INTRODUCTION .............................................................................................................22
5.1 Rationale and Background ................................................................................22
5.2 Purpose of the Study ..........................................................................................22
5.3
Risks and Benefits .............................................................................................23
6STUDY  OBJECTI VES ......................................................................................................24
6.1 Primary  Objective(s)
.........................................................................................24
6.2 Secondary  Objective(s)
.....................................................................................24
24
6.4 Safety  Objective(s) ............................................................................................24
7INVESTIGA TIONAL  PLAN ............................................................................................25
7.1 Study Design .....................................................................................................25
7.2 Rationale for Study  Design ...............................................................................27
7.3 Rationale for Duration of Treatment/Follow -Up...............................................27
7.4
Rationale for Choice of Control Product................................ ...........................27
7.5 Data Monitoring Committee ..............................................................................27
8STUDY  POPULA TION....................................................................................................27
8.1 Inclusion Criteria
...............................................................................................28
8.2 Exclusion Criteria ................................ ................................ ..............................29
8.3 Rescreening of Subjects ................................ ................................ ....................30
9TREA TMENTS ADMINISTERED ................................ ................................ ...................30
9.1 Investigational Product(s) ................................ ................................ ..................30
9.2 Other Medical Device or Medication Specified for Use During the Study ......34
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018

Page 3of 59
9.3 Treatment Assignment / Randomization ...........................................................34
9.4 Treatment masking ............................................................................................34
9.5 Accountability  Procedures .................................................................................36
9.6
Changes to concomitant medications, treatments/ procedures..........................37
10STUDY  PROCEDURES AND ASSESSMENTS .............................................................37
10.1 Informed Consent and Screening
......................................................................38
10.2 Description of Study  Procedures and Assessments ...........................................39
10.2.1 Demographics ....................................................................................39
10.2.2
Medical History .................................................................................39
10.2.3
Investigational Product compliance ..................................................39
10.2.4 Adverse Event Collection: Safety  Assessment ..................................39
10.2.5 Biomicroscop y: Safety  Assessment ...................................................39
10.2.6 Device Deficiencies: Safety  Assessment ...........................................39
39
10.3 Unscheduled V isits............................................................................................40
10.4 Discontinued Subjects .......................................................................................41
10.4.1 Screen Failures ..................................................................................41
10.4.2 Discontinuations ................................................................................41
10.4.3 Schedule of Procedures and Assessments for Subjects Discontinued 
from Investigational Product
.............................................................42
10.5 Clinical Study  Termination ................................................................................42
10.5.1 Follow -up of subjects after study  participation has ended ................
42
11ADVERSE EVENTS AND DEVICE DEFICIENCI ES...................................................42
11.1
General Information ..........................................................................................42
11.2Monitoring for Adverse Events .........................................................................45
11.3
Procedures for Recording and Reporting ................................ ..........................46
11.4Return product anal ysis................................ ................................ .....................48
11.5Unmasking of the Study  Treatment...................................................................48
11.6Follow -Up of Subjects with Adverse Events ................................ .....................48
11.7Pregnancy  in the Clinical Study ................................ ................................ ........49
12ANAL YSIS PL AN................................ ................................ ................................ ............49
12.1 Subject Evaluability ................................ ................................ ...........................49
12.2 Analy sis Sets ................................ ................................ ................................ .....49
12.2.1 Saf ety Analysis Set ................................ ................................ ............49
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018

Page 4of 59
12.2.2 Full Anal ysis Set ................................................................................49
12.2.3 Per Protocol Anal ysis Set ..................................................................50
12.3
Demographic and Baseline Characteristics.......................................................50
12.4 Effectiveness Anal yses......................................................................................50
12.4.1 Analy sis of Primary  Effectiveness Endpoint(s) .................................50
12.4.1.1 Statistical Hy potheses ........................................................50
12.4.1.2 Analy sis Methods ..............................................................50
12.4.2 Analy sis of Secondary  Effectiveness Endpoints ............................... 51
12.4.2.1 Statistical Hy potheses ........................................................51
12.4.2.2 Analy sis Methods ..............................................................51
.......................
51
52
53
12.5 Handling of Missing Data .................................................................................53
12.6 Safety  Analyses.................................................................................................53
54
12.8 Sample Size Justification ...................................................................................54
13DATA HANDLING AND ADMINISTRA TIVE REQUI REMENTS ...............................
54
13.1 Subject Confidentiality ......................................................................................54
13.2 Completion of Source Documents and Case Report Forms ..............................
55
13.3 Data Review and Clarifications.........................................................................56
13.4 Sponsor and Monitoring Responsibilities .........................................................56
13.5 Regulatory  Documentation and Records Retention ..........................................56
13.6 Quality  Assurance and Quality  Control .............................................................57
14ETHI CS.............................................................................................................................57
15REFERENCES ................................ ................................ ................................ ..................59
15.1 References applicable for all clinical studies ................................ ....................59
15.1.1 US references applicable for clinical studies.....................................59
15.2 References for this clinical study ......................................................................59
List of Tables
Table2–1 List of Acron yms and Abbreviations Used in This Protocol ...........................10
Table3–1 Schedule of Study  Procedures and Assessments ................................ .............19
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018

Page 5of 59
Table6–1 Primary  Objective(s) ................................ ................................ ........................24
Table6–2 Secondary  Objective(s) ................................ ................................ ....................24
Table6–3 Safety  Objective(s) ................................ ................................ ...........................24
Table9–1 Test Product ................................ ................................ ................................ .....30
Table9–2 Control Product ................................ ................................ ................................32
34
List of Figur es
Figure 7-1 Study  Flow Chart ................................ ................................ .............................26
Figure 11–1 Categorization of All Adverse Events ................................ ..............................43
Figure 11-2 Categorization of All Serious Adverse .............................................................43
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018

Page 6of 59
1GLOSSAR Y OF TERMS
Names of test product(s) DAILIES®AquaComfort Plus®Digital Soft Contact Lenses
(DACP  Digital)
Name of Control Product(s) DAILIES®AquaComfort Plus®Sphere Soft Contact Lenses
(DACP)
Adverse Device Ef fect Adverse event related to the use of a n investigational 
medical device (test product ) or control product. Note: This 
definition includes adverse events r esulting fr om insufficient 
or inadequate instructions for use, deployment, 
implantation, installation, or operation; any malfunc tion; 
and use err or or intentional misuse of the test pr oduct or 
contr ol pr oduct.
Adverse Event Any untoward medical occurrence, unintended disease or 
injury , or untoward clinical signs (including abnormal 
laboratory  findings) in subjects, users or other persons, 
whether or not related to the investigational medical device 
(test product). Note: For s ubjects, this definition includes 
events r elated to the test pr oduct, the contr ol product, or the 
procedur es involved. For users or other persons, this 
definition is r estricted to events r elated to the test pr oduct.
Requirements for reporting Adverse Event s in the study  can 
be found in Section 1 1.
Anticipate d Serious 
Adverse Device Ef fectSerious adverse device effect which b y its nature, incidence, 
severit y,or outcome has been identified in the risk 
management file.
Device Deficiency Inadequacy  of a medical device with respect to its identity , 
quality , durability , reliability , safety , or performance. Note: 
This definition includes malfunctions, use err ors, and 
inadequate labeling.
Requirements for reporting Device Deficiencies in the s tudy 
can be found in Section 1 1.
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018
Page 7of 59
Enrolled Subject Any subject who signs an informed consent form for 
participation in the study .
Interventional Clinical T rial A research trial that prospectivel y assigns, whether 
randomly  or not, human participants or groups of humans to 
one or more health -related interventions to evaluate the 
effects on health outcomes, and/or a research trial in which 
diagnostic or monitoring procedures bey ond standard of care 
are conducted and generate outcomes for use in analy sis of
data.
Investigational Product Is defined as a preventative (vaccine), a therapeutic (drug or 
biologic), device, diagnostic, or palliative used as a test or 
control product in a clinical trial, including a product with a 
marketing authorization when used or assembled 
(formulated or packaged) in a way  different from the 
authorized form, or when used for an unauthorized 
indication, or when used to gain further information about 
the authorized form .
Malfunction Failure of a medical device to perform in accordance with its 
intended purpose when used in accordance with the 
instructions for use or clinical investigation plan.
Non-serious Adverse Event Adverse event that does not meet the criteria for a serious 
adverse event.
Randomized Subjects Any subjec t who is a ssigned a randomized treatment.
Serious Adverse Device 
Effect (SADE)Adverse device ef fect that has resulted in any of the 
consequences characteristic of a serious adverse event.
Serious Adverse Event 
(SAE)Adverse event th at led to any  of the following:
Death.
A serious deterioration in the health of the subject 
that either resulted in:
a.a life -threatening illness or injury .
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018
Page 8of 59
Note: Life -threatening means that the 
individual was at immediate risk of death fr om 
the event as it occurr ed, ie, it does not include 
an event which hypothetically might have 
caused death had it occurr ed in a mor e sever e 
form.
b.any potentially  sight -threatening event or 
permanent impairment to a body structure or a 
body  function.
c.in-patient hospitalization or prolonged 
hospit alization.
Note: Planned hospitalization for a pr e-
existing condition, without serious 
deterioration in health, is not consider ed a 
serious adverse event. In general, 
hospitalization signifies that the individual 
remained at the hospital or emer gency war d 
for observation and/or tr eatment (usually 
involving an overnight stay) that would not 
have been appr opriate in the physician's office 
or an out -patient setting. Complications that 
occur during hospitalization ar e adverse 
events. If a complication pr olongs 
hospitalization or fulfills any other serious 
criteria, the event is serious. W hen in doubt as 
to whether “ hospitalization ” occurr ed, the 
event should be consider ed serious.
d.a medical or surgical intervention to prevent 
a) or b). 
e.any indirect harm as a co nsequence of 
incorrect diagnostic test results when used 
within manufacturer ’s instructions for use.
Fetal distress, fetal death, or a congenital abnormality  
or birth defect.
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018
Page 9of 59
Refer to Section 1 1 for additional SAEs.
Significant Non -Serious 
Adverse EventIs a sy mptomatic, device -related, non -sight threatening 
adverse event that warrants discontinuation of any  contact 
lens wear for greater than or equal to 2 weeks.
Refer to Section 1 1 for additional Significant Non -Serious 
AEs.
Unanticipated Serious 
Adverse Device Ef fect 
(USADE)Serious adverse device effect which b y its nature, incidence, 
severit y or outcome has not been identified in the risk 
management file.
Use Error Act or omission of an act that results in a dif ferent medical 
device response than intended by  manufacturer or expected 
by user. Note: This definition includes slips, lapses, and 
mistakes. An unexpected physiological r esponse of the 
subject does not in its elf constitute a use err or
.
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018
Page 10of 59
2LIST  OF ACRONYMS AND ABBREVIA TIONS
Table2–1 List of Acronyms and Abbr eviations Used in This Pr otocol
Abbreviation Definition
ADE Adverse device effect
AE Adverse event
DACP or DACP  
lens(es)DAILIES AquaComfort Plus Sphere Soft Contact L enses
DACP  Digital or 
DACP  Digital 
lens(es)DAILIES AquaComfort Plus Digital Soft Contact L enses
BCVA Best corrected visual acuity
CFR Code of Federal Regulations
CI Confidence interval
CRF Case report form
CSM Clinical site manager
CTT Clinical trial team
D Diopter
D/C Discontinue
DEP Deviations and evaluability  plan
eCRF Electronic case report f orm
EDC Electronic data capture
FAS Full Anal ysis Set
FDA Food and Drug Administration
GCP Good Clinical Practice
IB Investigator’s brochure
ICF Informed consent form
ICH International Council for Harmonisation of Technical Requirements 
for Pharmaceuticals for Human Use
IEC Independent ethics committee
IP Investigational product
IRB Institutional review board
IRT Interactive response technology
ISO International Organization of Standardization
LCSM Lead clinical site manager
LID Lens identification
LogMAR Logarithm of the minimum angle of resolution
MEDDEV Designation indicating a guidance document from the European 
Commission
mm Millimeter
MOP Manual of procedures
N Number
N/A Not applicable
OD Right ey e
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018
Page 11of 59
Abbreviation Definition
OS Left ey e
OU Both ey es
PP Per protocol a nalysis set
pt Point
PVA Polyvinyl alcohol
RAVE Medidata electronic data capture and management
SADE Serious adverse device effect
SAE Serious adverse event
SD Standard deviation
SLE Slit-lamp examination
SOP Standard operating procedure
US United States
USADE Unanticipated serious adverse device effect
VA Visual acuity
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018
Page 12of 59
3PROTOCOL  SUMMAR Y
This is a prospective, randomized, bilateral crossover , double -masked, controlled study . The 
study  population will include approximately  60subjects across approximately  4US site s
enrolling approximately  15 su bjects per site to meet the required target of 48 completed 
subjects . The stud y will consist of volunteer subjects with normal eyes (other than correction 
for refractive error) aged 18 to 35. Subjects should have at least 2months of experience 
wearing DAC P soft contact lenses on a daily  wear , daily  disposable basis , be usingdigital 
devices at least 4 hours per day  at least 5 day s per week, and experience sy mptoms of ey e 
strain.
Subjects will be randomly assigned in a 1:1 manner to either receive DACP  Digital or DACP
lenses for use during Period 1 of the study . For Period 2, the contact lenses that were not 
allocated for use in Period 1 will then be
assigned per the specified sequence group:
Sequence Group
1)DACP  Digital → DACP
2)DACP → DACP  Digital
Subjects will wear each study  product in a daily  wear , dail y disposable modality  for 
7
± 2days per study  product , with up to 4 scheduled visits.
Visit 1 –Baseline/Fitting
Visit 2 –Dispense Study  Product 1 [0 -7 day s from Visit 1]
Visit 3 – 1-W eek Follow - up Study  Product 1 [7 ± 2 day s from Visit 2] / Dispense 
Study  Product 2
Visit 4 – 1-W eek Follow - up Study  Product 2 [7 ± 2 day s from Visit 3] / Exit
The following assessments will be performed for each study  product (see S ection 10 for 
details):
Dista nce VA withstudy  lenses ( logMAR , OU) 
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018

Page 13of 59
Subjects will also be asked to complete the following series of questionnaires related to their 
lens wearing experiences with each stud y product:
Investigational 
product typeDevice
Study type Interventional
Investigational 
productsTest Product : DACP Digital lenses
Control Product : DACP lenses
Purpose and 
rationaleThe overall purpose of this study is to evaluate the visual 
performance of the DACP Digital lens by assessing Distance VA 
as the primary  variable compared to the commercially  available 
DACP lens.
Objective(s)The primary  objective is to demonstrate noninferiority  in 
Distance V A with DACP
 Digital when compared to DACP  
at the 1 -Week Follow-up V isit.
The secondary  objective is to demonstrate noninferiority  in 
subjective overall vision with DACP  Digital when 
compared to DACP  at the 1 -Week Follow-up V isit.
Endpoint(s) Primary  Effectiveness
Distance V A (logMAR, OU )
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018

Page 14of 59
Secondary  Effectiveness
Overall V ision
 
Safety
AEs
Biomicroscop y findings 
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018

Page 15of 59
Device deficiencies
Assessment(s) Effectiveness
Distance VA with habitual co rrection ( logMAR )
Subjective ratings as related to  vision ,  
 
Safety
AEs
Biomicroscop y
Device deficiencies
Study Design This is a prospective, randomized, bilateral crossover , double -
masked, controlled study .Subject participation in the study  will be 
approximately  2 weeks with up to 4 visits where subjects will 
bilaterally  wear the 1ststudy  lens from the assigned lens sequence 
(Study  Product 1) for approximately  7 ±2 day sbefore crossing 
over into 
the 2ndstudy  lens of the assigned lens sequence (Study  
Product 2) bilaterall y for approximately 7 ±2 day s .
Subject population Volunteer subjects aged 18 to 35 with normal ey es (other than 
correction for refractive error), currentl y wearing DACP  soft 
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018

Page 16of 59
contact l enses on a dail y wear , daily  disposable basis. Subjects 
should have at least 2months of DACP  wearing experience, wear 
these lenses at least 5 day s per week and at least 8 hours per day , 
use digital devices at least 4 hours per day  at least 5 day s per 
week , experience symptoms of ey e strain , and require distance 
contact lenses in a power range from -
1.50 D to -3.75 D.
Key inclusion 
criteria
(See Section 8.1 for a 
complete list of 
inclusion criteria)Current wearers of commercial spherical DACP . Wearers 
with at least 2months wearing experience in their current 
DACP lenses , with a minimum wearing time of 5 day s per 
week and 8 hours per day .
Currently  using digital devices (computer, tablet, and/or 
smart phone) for a minimum of 5 day s per week an d 4 hours 
per day .
Currently  experiencing s ymptoms of ey e strain from using 
technology .
Requiring spherical contact lens distance correction in each 
eye within the range of -1.50 D to -3.75 D in 0.25 D steps.
Manifest astigmatism less than or equal to 0.75 D (at 
screening).
Best corrected distance VAgreater than or equal to 0.1 
(20/25 )in each ey e.
Key exclusion 
criteria
(See Section 8.2 for a 
complete list of 
exclusion criteria)Any anterior segment infection, inflammation, or 
abnormality  or disease (including s ystemic) that 
contraindicates contact lens wear, as determined by the 
Investigator.
History  of refractive surgery  or irregular cornea.
Ocular or intraocular surgery  within the previous 12 months 
(excluding placement of punctal plugs) or during the study .
Biomicroscop y findings at screening that are moderate 
(Grade 3) or higher and/or corneal vascularization that is 
mild ( Grade 2) or higher in either eye at screening.
Current or history  of herpetic keratitis in either eye.
Eye injury  within 12weeks immediately  prior to enrollment 
for the stud y.
Wearing habitual contact lenses in an extended wear 
modality  (routinely sleeping in lenses for at least 1 night per 
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018
Page 17of 59
week) over the last 3 months prior to enrollment.
Data analysis and 
sample size 
justif icationTo address the primary  and secondary  effectiveness endpoints, 
planned anal yses are summarized below:
Endpoint Comparison Statistical Method
Primary
Distance VA DACP Digital vs. DACP
Noninferiorit y 
(margin =0.05 logMAR)Mixed effect 
repeated measures 
model
Secondary
Overall vision DACP Digital vs. DACP
Noninferiorit y 
(margin = 1.0)Mixed effect 
repeated measures 
model
A sequential gatekeeping strategy  will be implemented to control 
multiplicity , thereby  controlling the overall ty pe I error at one -
sided 0.05.
No inferential testing will be carried out for safet y endpoints.
Sample size calculation for primary  and secondary  effectiveness 
endpoints is summarized below:
Endpoint Assumptions Power N per 
sequence
Primary
Distance VA Paired 
differences 
SD= 0.09880% 
(one-sided α = 0.05)18
Secondary
Overall vision Paired 
differences 
SD= 2.2980% 
(one-sided α = 0.05)24
Key words DACP Digital
DACP
Visual a cuity
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018

Page 18of 59
Associated materials None. With the use of daily  disposable lens es, lens care is not 
required.
To prevent confounding the eff ectiveness endpoint s
, 
Use of lubrication/re- wetting drops will not be permitted at 
any time during study . 
Use of near aid (eg ,reading glasses) will not be permitted at 
any time during study .
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018
Page 19of 59
Table3–1 Schedule of Study Pr ocedur es and Assessments
Procedure/ Assessment
Pre-screeningVisit 1Visit 2
0-7 days
from  V1Visit 
3Visit 
3Visit 4
7 (±2) 
days
from  V3
Unscheduled Visit
Early Exit7 (±2) days
from  V2
Baseline/
FittingDispense 
Study 
Product
1
Follow-up
Study Product 1
Dispense
Study Product 2
Follow-up
Study Product 2 /
Exit
Digital Use Time *   
Symptomatology Questionnaire *
Informed consent 
Dem ographics 
Medical history      
Concomitant Medications  () ( ) () ()
)()
Inclusion/Exclusion 
Distance VA w/habitual lenses 
(logMAR, OD, OS)*
Over -refraction w/ habitual 
lenses (OD, OS)*
Manifest refraction*  () ( ) ( ) () ()
  () ( ) ( ) () ()
Biomicroscopy      
Dispense study lenses / Rx  
VA w/ study lenses (  
OU, logMAR distance)      ()
  
  
  () ()
 
sites)  () ()
   ()
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018

Page 20of 59
Procedure/ Assessment
Pre-screeningVisit 1Visit 2
0-7 days
from  V1Visit 
3Visit 
3Visit 4
7 (±2) 
days
from  V3
Unscheduled Visit
Early Exit7 (±2) days
from  V2
Baseline/
FittingDispense 
Study 
Product
1
Follow-up
Study Product 1
Dispense
Study Product 2
Follow-up
Study Product 2 /
Exit
Subjective ratings with study 
lenses  ()
 () ()
    ()()
   ()()
()()
AEs      
Device deficiencies      
Exit form () ( ) ( )  ()
() assessment performed as necessary , eg, decrease of V Aby 2 lines or more with investigational product (IP)
* Source only
4PROTOCOL  AMENDMENTS
Modification of the protocol is prohibited without prior written agreement in the form of a 
protocol amendment. All amendments must be created b y the Study Sponsor and must be 
approved b y the IRB/IEC and global and regional Health Authorities, as applicable, prior to 
implementation except when required to mitigate immediate safet y risks or when the changes 
involve only  logistical or administrative revisions. 
Amendments may necessitate that the informed consent and other study -related material be 
revised. If the consent form is revised, all subjects currentl y enrolled in the study  must sign 
the approved, revised informed consent (re-consent) , as required b y the IRB/IEC.
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018

Page 21of 59
4.1 Amendments
Amendment 1
Purpose of Amendment:  To clarify  Inclusion Criteria for subject eligibility
Rationale:  Revision of certain Inclusion Criteria to improve enrollment rate across all sites 
without compromising quality  of data
Current Study  Status:  Active , enrolling subjects.
Case Report Form Revision Required: Yes XNo
Informed Consent Modifications Required: Yes XNo
Applicable Investigators: X All Selected (list below)
Itemized Changes:
1Changed From Section 3:
Subjects should have at least 3 months of 
experience wearing DACP  soft contact 
lenses on a dail y wear , daily  disposable 
basis, be using digital devices at least 4 
hours per day  at least 5 day s per week, and 
experience sy mptoms of ey e strain .Changed To Sec tion 3:
Subjects should have at least 2 months of 
experience wearing DACP  soft contact 
lenses on a dail y wear , daily  disposable 
basis, be using digital devices at least 4 
hours per day  at least 5 day s per week, and 
experience sy mptoms of ey e strain .
2Changed From Section 3 (Subject 
Population):
Subjects should have at least 3 months of 
DACP  wearing experience, wear these 
lenses at least 5 day s per week and at least 
8 hours per day , use digital devices at least 
4 hours per day  at least 5 day s per week, 
experience sy mptoms of ey e strain , and 
require distance contact lenses in a power 
range from 
-1.50 D to - 3.75 D.Changed To Section 3 (Subject 
Population):
Subjects should have at least 2 months of 
DACP  wearing experience, wear these 
lenses at least 5 day s per week and at least 
8 hours per day , use digital devices at least 
4 hours per day  at least 5 day s per week, 
experience sy mptoms of ey e strain , and 
requir e distance contact lenses in a power 
range from -1.50 D to - 3.75 D.
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018
Page 22of 59
3Changed From Section 3 (Key Inclusion 
Criteria):
Current wearers of commercial spherical 
DACP . Wearers with at least 3 months 
wearing experience in their current DACP
lenses, with a minimum wearing time of 5 
days per week and 8 hours per day .Changed To Section 3 (Key Inclusion 
Criteria):
Current wearers of commercial spherical 
DACP . Wearers with at least 2 months 
wearing experience in their current DACP
lenses, with a minimum wearin g time of 5 
days per week and 8 hours per day .
4Changed From Section 8.1 (Inclusion 
Criteria) :
Current wearers of commercial spherical 
DAILIES AquaComfort Plus . Wearers with 
at least 3 months wearing experience in 
their current DAILIES AquaComfort Plus
correction, with a minimum wearing time 
of 5 day s per week and 8 hours per day .Changed To Section 8.1 (Inclusion 
Criteria) :
Current wearers of commercial spherical 
DAILIES AquaComfort Plus . Wearers with 
at least 2 months wearing experience in 
their curr ent DAILIES AquaComfort Plus
correction, with a minimum wearing time 
of 5 day s per week and 8 hours per day .
5INTRODUCTION
5.1 Rationale and Backgr ound
The objective of the DACP  Digital project is to introduce a modification to the DAILIES 
AquaComfort Plus Contact Lens (DACP) family ,  
  
 
This clinical evaluation is a performance verification trial  
 The primary  and secondary  endpoints were selected to fulfil the primary  
and secondary  objectives of the study . Procedures for measurement of these endpoints were 
selected based on common practice for these assessments. 
5.2 Purpose of the Study
The overall purpose of this study  is to evaluate the visual performance of the DACP Digital 
lens by  assessing Distance VA as the primary  variable compared to the commercially  
available DACP lens.
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018

Page 23of 59
At the end of the s tudy, a clinical study  report will be prepared in accordance with applicable 
regulatory  requirements and standards.
There are no immediate plans to submit the results of this development study  for publication; 
however , the results may  be of fered for public ation if they  are of scientific interest, or if the 
results relate to a product that is subsequently  approved or cleared for marketing.
5.3 Risk s and Benefits
Contact lenses are intended to of fer correction of ametropia, improved peripheral (side) 
vision, the convenience of not wearing spectacles, a non -permanent device application, and a 
perceived improvement of cosmetic appearance (over spectacles). Material properties and 
design characteristics of DACP Digital lenses are features consistent with successful c ontact 
lens wear .
Clinical studies involving DACP  Digital have not y et been conducted . However , the core lens 
material used for DACP  Digital is identical to the currentl y marketed DACP , for which there 
are multiple clinical studies, postmarket data, and literature reports that established a positive 
benefit/risk ratio for the lens .
In general, the risks with DACP  Digital are anticipated to be similar to other marketed daily  
wear daily  disposable contact lenses. Specifically , the safet y profile is expected to be similar 
to other lenses in the nelfilcon A family  since the core lens material used for DACP  Digital is 
identica l toDACP .
DACP  Digital is intended for single use, dail y disposable wear . Since DACP  Digital is 
disposed of after a single use, lens care cleaning or disinfecting products are not needed and 
were not tested.
A summary  of the known potential risks and benefits associated with DACP  Digital lenses 
can be found in the IB.Any risks to subjects in this trial are minimized by  compliance with 
the eligibility  criteria and study  procedures, and through close supervisio n by a licensed 
clinician during exposure to the study  lenses. 
There may  also be unknown risks with the use of DACP  Digital lens. During clinical 
exposure, study  conditions, controls and oversight by  qualified ey e care professionals are 
factors designed t o further minimize risk to study  subjects. Under the conditions of these 
studies, adequate informed consent and subject instructions, scheduled wear , replacement and 
follow -up visit schedules, risks to study  subjects are controlled and minimized.
  
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018
Page 24of 59
Refer t o the IB for additional information.
6STUDY  OBJECTIVES
6.1 Primary Objective(s)
Table6–1 Primary Objective(s)
Objective(s) Endpoint(s)
Demonstrate noninferiority  in Distance VA 
with DACP  Digital when compared to 
DACP at the 1-W eek Follow-up V isit.Distance V A (logMAR , OU)
6.2 Secondary Objective(s)
Table6–2 Secondary Objective(s)
Objective(s) Endpoint(s)
Demonstrate noninferiority  in subjective 
overall vision with DACP  Digital when 
compared to DACP  at the 1-W eek Follow-
up V isit.Overall V ision
6.4 Safety Objective(s)
Table6–3 Safety Objective(s)
Objective(s) Endpoint(s)
Describe the safety  profile of the 
investigational productsAEs
Biomicroscop y findings
Device Deficiencies
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018

Page 25of 59
7INVESTIGA TIONAL  PLAN
7.1 Study Design
This is a prospective, randomized, bilateral crossover , double -masked, controlled study .
The study  population will include volunteer subjects with normal ey es (other than correction 
for refractive error) aged 18 to 35, and have at least 2 months of experience wearing DACP 
soft contact lenses on a daily  wear , daily  disposable basis. Subjects mu st be usingdigital 
devices at least 4 hours per day  at least 5 day s per week, and experience sy mptoms of ey e 
strain.
Subjects will be randomly assigned in a 1:1 manner to either receive DACP  Digital or DACP  
lenses for use during Period 1 of the study . For Period 2, the contact lenses that were not 
allocated for use in Period 1 will then be assigned per the specified sequence group:
Sequence Group
1)DACP  Digital 
→ DACP
2)DACP  → DACP  Digital
Subjects will wear each study  product bilaterall y in a daily  wear , dail y disposable modality 
for 7
± 2days per IP, with up to 4 scheduled visits.
Visit 1 – Baseline/ Fitting
Visit 2 – Dispense Study  Product 1 [0 -7 days from Visit 1]
Visit 3 – 1-W eek Follow -up Study  Product 1 [7 ± 2 day s from Visit 2] / Dispense 
Study  Product 2
Visit 4 
– 1-W eek Follow -up Study  Product 2 [7 ± 2 day s from Visit 3] / Exit
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018
Page 26of 59
Figur e 7-1 Study Flow Chart
DACP  Digital DACP
DACP  Digital DACPPrescreening
(via chart review and screening questions)
Habitual Sy mptomatic DACP  wearers
Order IP
Visit 3
7 day s (±2 day s) from Visit 2
Follow -up Study  Product 1 / Dispense Study  Product 2
Visit 4
7 day s (±2 day s) from Visit 3
Follow -up Study  Product 2 / ExitVisit 2
Dispense Study  Product 1
(0 –7 day s from V isit 1)Visit 1
Baseline / Fitting
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018
Page 27of 59
7.2 Rationale for Study Design 
In this study , the on -eye performance of the investigational DACP  Digital lens and the 
commerciall y available DACP  lens will be assessed in a prospective, double -masked, 
bilateral crossover design with 7 ± 2 day s of exposure to each study  lens. The study  design as 
well as the exposure duration of study  lenses is supported by  the nonclinical and clinical data 
presented in the IB. The study  design is well -established.
7.3 Rationale for Duration of Treatment/ Follow-Up
The duration of exposure to the investigational product was chosen to address the objective 
of this study , and is aligned with the duration of use of the product in ac cordance with 
product labeling.
7.4 Rationale for Choice of C ontrol Product
DACP  lenses were chosen as the control product to address the stud y objectives.
DACP contact lenses were chosen as the control product because these lenses have the same 
wear modalit y, material, and parameters to the test product DACP Digital, and are the 
spherical design as compared to the test product’s aspherical design .
7.5 Data Monitorin g Committee
Not Applicable .
8STUDY  POPULA TION
The intended stud y population consists of v olunteer subjects aged 18 to 35 with normal ey es 
(other than correction for refractive error), currently  wearing DACP  soft contact lenses on a 
daily  wear , daily  disposable basis. Subjects should have at least 2 months of DACP  wearing 
experience, wear these lenses at least 5 day s per week and at least 8 hours per day , use digital 
devices at least 4 hours per day  at least 5 day s per week, experience symptoms of ey e strain, 
andrequire distance contact lenses in a power range from -1.50 D to -3.75 D.
It is aimed to enroll approximately  60subjects in approximately  4sites in the US , with a n 
approximate target of 15 subjects per site. Site- specific targets may vary based upon
individual site capabilities. Estimated time needed to recruit subjects for the study  is 
approximately  4weeks.
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018
Page 28of 59
8.1 Inclusion Criteria
Written informed consent must be obtained before any study  specific assessment is 
performed. Upon signing informed consent, the subject is considered enrolled in the study .
Subjects eligible for inclusion in this study  must fulfill allof the following criteria:
1. Subjects must be 18 to 35 y ears of age and be able to understand and sign an 
IRB/IEC approved Informed C onsent form.
2. Current wearers of commercial spherical DAILIES AquaComfort Plus . Wearers 
with at least 2months wearing experience in their current DAILIES AquaComfort 
Plus correction, with a minimum wearing time of 5 days per week and 8 hours per 
day.
3. Requiring spherical contact lens distance correction in each ey e within the range 
of -1.50 D to -3.75 D in 0.25 D steps.
4. Currently  experiencing s ymptoms of ey e strain from using technology .
5. Subjects are willing to wear the stud y lenses each day as possible (including the day  
of the follow -up visits) and at least 8 hours per day  unless contact lens wear is 
contraindicated.
6. Subject must possess spectacles that provide a corrected visual acuit y of 0.40
(20/40 )or better OU and be willing to wear them (as needed).
7. Manifest astigmatism less than or equal to 0.75 D (at screening)
8. Best corrected distance visual acuity  greater than or equal to 0.10 ( 20/25 )in each 
eye (as determined by  manifest refraction at screening).
9. Willing to NOT  use rewetting/lubricating drops at any  time during the study .
10. Currently  using digital devices (computer , tablet, and/or smart phone) for a 
minimum of 5 day s per week and 4 hours per day .
11. Willing to NOT  use an y near aid (eg, reading glasses) at any  time during the study .
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018
Page 29of 59
8.2 Exclusion C riteria
Subjects fulfilling anyof the following criteria are not eligible for participation in this study .
1. Any anterior segment infection, inflammation, disease, or abnormalit y that 
contraindicates contact lens wears as determined by the Investigator .
2. Any use of s ystemic medications or ocular medications for which contact lens wear 
could be contraindicated, as determined b y the Investigator , including use of any  
topical ocular medications and lubrication drops that would require instillation 
during contact lens wear.
3. History  of refractive surgery  or irregular cornea.
4. Ocular or intraocular surgery wit hin the previous 12 months (excluding placement of 
punctal plugs) or during the study .
5. Biomicroscop y findings at screening that are moderate ( Grade 3) or higher and/or 
corneal vascularization that is mild ( Grade 2) or higher in either ey e at screening.
6. Current or history  of pathologicall y dry eye in either ey e.
7. Current or history  of herpetic keratitis in either eye.
8. Eye injury  within 12weeks immediately  prior to enrollment for the study
9. Wearing habitual contact lenses in an extended wear modality  (routinel y sleeping in 
lenses for at least 1 night per week) over the last 3 months prior to enrollment.
10. Monocular subjects (onl y one ey e with functional vision).
11. Known pregnancy  at time of enrollment.
12. Concurrent participation of the subject in a contact lens or contact lens care product 
clinical trial or within the previous 30 day s.
13. The Investigator , his/her staf f, family  members of the Investigator , family  members 
of the Investigator’ s staf f, or individuals living in the households of the 
aforementioned persons may  not participate in the study .
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018
Page 30of 59
8.3 Rescreening of Subjects
Subjects must be screened according to the full list of inclusion/exclusion criteria in 
Section 8.1 and 8.2 of this protocol.
After informed consent is signed, a separate screening visit is allowed for the following 
criteria:
INC01 –Subject must be 18 to 35 y ears of age
EXC12 – Participation of the subject in a clinical trial within the previous 30 days or 
currentl y enrolled in an y clinical trial
This separa te screening visit can take place regardless of whether any  other criterion has been 
verified.
Rescreening of subjects is not allowed in this study
.
9TREATMENTS ADMINISTERED
9.1 Investigational Pr oduct(s)
Test Pr oduct(s): DACP  Digital soft contact lenses (LID 014466)
Contr ol Pr oduct(s) (If applicable): DACP  Sphere soft contact lenses (LID007861)
Table9–1 Test Pr oduct
Test Product DAILIES AquaComfort Plus Digital 
Soft Contact L enses (DACP 
Digital) (LID 014466 )
Manufacturer Alcon Laboratories, Inc.
6201 South Freeway
Fort Worth, Texas 76134-2099
USA
Indication for use 
and intended 
purpose in the 
current stud y The intended purpose of this contact lens is for the vision 
correction. 
A limited range of powers is available for use in this study  in 
accordance with the study objective.
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018
Page 31of 59
Product description 
and parameters 
available for this 
studyMaterial: Nelfilcon A
Water content : 69%
Power range: -1.50 D to -3.75 D in 0.25 D steps
Base curve (mm) :
8.7 (target)
Diameter (mm) :
14.0 (target)
Other: Additional details can be found in the IB
Formulation NA
Usage Wear:
oDaily  Wear
oBilateral
Replacement period: Daily  Disposable
Exposure: 7 ± 2 day s and a t least 8 hours per day
Lens Care: N/A
Additional details can be found in the MOP
Number/Amount of 
product to be 
provided to the 
subjectA box containing 1 0lenses (per ey e) will be provided to the subject 
ateither Visit 1 or Visit 2, based on the subject ’s randomized 
sequence assignment .
Packaging 
descriptionBlister containing phosphate buf fered saline solution with wetting 
agents
Labeling description Lens Foil label includes:
-material name and /oridentifier
-base curve
-diameter
-manufacturing protocol number
-packing solution
-power
-lot number
-expiration date
-content statement
- investigational device statement
-Sponsor information
Provided in boxes of 10 lenses per power per box, identified 
with the following:
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018
Page 32of 59
-a color coded label stating the protocol number
-identifier
-power
-an investigational use only statement
-tracking number
Storage conditions Stored at room temperature. 
Additional 
identify ing 
informatio nN/A
Supply Refer to the MOP for a detailed description
Table9–2 Contr ol Pr oduct
Control Product(s) DAILIES AquaComfort Plus Sphere Soft Contact L enses (DACP)
(LID007861)
Manufacturer Alcon Laboratories, Inc.
6201 South Freeway
Fort Worth, Texas 76134-2099
USA
Indication for Use The intended of this contact lens is for the vision correction .
A limited range of powers is available for use in this study  in 
accordance with the study objective.
Product description 
and parameters 
available for this 
studyMaterial: Nelfilcon A
Water content: 69%
Power range: -1.50 D to -3.75 D in 0.25 D steps
Base cur ve (mm): 8 .7
(target)
Diameter (mm): 14 .0 (target)
Other: Additional details can be found in the IB
Formulation Nelfilcon A. Additional details can be found in the IB for DACP.
Usage Wear:
oDaily  Wear
oBilateral
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018
Page 33of 59
Replacement period: Daily  Disposable
Exposure: 7 ± 2 days and at least 8 hours per day
Lens Care: N/A
Additional details can be found in the MOP
Number/Amount of 
Product to be 
Provided to the 
subjectA box containing 1 0lenses (per ey e) will be provided to the subject 
ateither Visit 1 or Visit 2, based on the subject ’s randomized 
sequence assignment .
Packaging 
descriptionBlister containing phosphate buf fered saline solution with wetting 
agents
Labeling description Lens Foil label includes:
-material name and /oridentifier
-base curve
-diameter
-packing solution
-power
-lot number
-expiration date
-content statement
- investigational device statement
- Sponsor information
Provided in boxes of 10 lenses per power per box, identified 
with the following:
- a color coded label stating the protocol number
-identifier
-power
-an investigational use only statement
-tracking number
Storage conditions Stored at room temperature. 
Additional 
identify ing 
informationN/A
Supply Refer to the MOP for a detailed description
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018
Page 34of 59
9.2 Other Medical Device or Medication Specified for Use During the 
Study
No other medical devices or medications are required to be used in conjunction with the 
treatments during the clinical study .
9.3 Treatment Assignment / Randomization
Subjects will be randomized in a 1 :1ratio to receive trea tment in crossover sequence DACP  
Digital then DACP or DACP then DACP  Digital respectivel y.
Only  after signing the ICF , a subject will be assigned a subject number by  the electronic data 
capture s ystem. 
A randomization list will be generated using a valida ted sy stem that automates the random 
assignment of treatment arms to randomization numbers in the specified ratio. Subjects will 
be assigned treatment according to the randomization list uploaded in the iMedidata 
BALANCE s ystem. The randomization list willbe generated and maintained by the Study  
Sponsor .
IRT
At V isit 1, all eligible subjects will be randomized via the EDC/I RT integration sy stem to one 
of the treatment arms. The Investigator or delegate will access the respective system after 
confirming tha t the subject meets all the eligibility  criteria. A randomization number will be 
automatically  assigned to the subject according to the subject randomization list but will not 
be communicated to the site user . The EDC/IR T integration sy stem will inform the site user 
of the treatment sequence assignment to be dispensed 
to the subject.
9.4 Treatment mask ing
This study  is double -masked, with subjects randomized to use DACP  Digital andDACP
lenses (in a crossover fashion) for the duration of the 7 ± 2 day treatment period for each lens 
product .  
 
 
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018

Page 35of 59
 
 
 
 
 
  
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
  
 
.
 
 
  
 
 
 
 
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018

Page 36of 59
This level of masking will be maintained throughout the conduct of the study . Unmasking 
will occur only  after all planned study  data have been validated, and the database locked. 
Masked study  personnel must avoid seeking information that may  compromise masking. 
Unmasked study  personnel must not disseminate information that is potentially  unmasking to 
any masked personnel. The masked and unmasked site personnel must coordinate all study  
activities as necessary  to protect masking and minimize bias during the study . 
In the event of a medical emergency where the knowledge of subject treatment is required, an 
individual I nvestigator will have the ability  to unmask the treatment assignment for a specific 
subject after contacting an appropriate Stud y Sponsor representative if time allows. 
Unmasking must be done according to the instructions provided for the study IRT system.
9.5 Accountability Procedures
Upon receipt of the IPs, the Investigator or delegate must conduct an inventory . During the 
study , unma sked designated study  staff must provide the I Ps to the subjects in accordance 
with their randomization assignment. Throughout the study , the Investigator or delegate must 
maintain records of IP  dispensation and collection for each subject. This record mus
t be made 
available to the stud y monitor for the purposes of verifying the accounting of IP  supplies. 
Any discrepancies and/or deficiencies between the observed disposition and the written 
account must be recorded along with an explanation. All IPs sent to the Investigator must be 
accounted for b y Study Sponsor personnel, and in no case be used in an unauthorized 
situation.
It is the Investigator ’s responsibility  to ensure that:
All study  products are accounted for and not used in any  unauthorized manner
All used foils and unused supplies are returned b y each subject
All unused products are available for return to the Study  Sponsor , as directed
Any study  lenses associated with a device deficiency  or with any  product -related 
adverse event (ie, ADE or SADE) ar e returned to the Study  Sponsor for investigation, 
unless otherwise directed by  the S ponsor . Refer to Section 1 1 of this protocol for 
additional information on the reporting of device deficiencies and AEs and the return 
of study  products associated with th ese events.
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018
Page 37of 59
9.6 Changes to concomitant medications, tr eatments/ procedur es
Changes i n concomitant treatments after Visit 1 are not allowed unless needed for the proper 
medical care and treatment of the subject for a specific medical condition.
After the subjec t is enrolled into the study , the Investigator must instruct the subject to notify  
the study  site about:
Any new medications 
Alterations in dose or dose schedules for current medications, 
Any medical procedure or hospitalization that occurred or is plann ed
Any non- drug therapies (including ph ysical therapy  and blood transfusions). 
The Investigator must document this information in the subject’ s case history  source 
documents.
10STUDY  PROCEDURES AND ASSESSMENTS
Subjects will wear each study  product in a dail y wear , dail y disposable modality  for 
7
± 2days per study  product , with up to 4 scheduled visits. Per I nclusion Criteria #5, s ubjects 
are willing to wear the study  lenses each day  as possible (including the day  of the follow -up 
visits) and at least 8 hour s per day  unless contact lens wear is contraindicated.
Visit 1 –Baseline/ Fitting
Visit 2 –Dispense Study  Product 1 [0 -7 day s from Visit 1]
Visit 3 – 1-Week Follow -up Study  Product 1 [7 ± 2 day s from Visit 2] / Dispense 
Study  Product 2
Visit 4 –
1-WeekFollow -up Study  Product 2 [7 ± 2 day s from Visit 3] / Exit
The following assessments will be performed for 
each study  product :
Distance V A with study  lenses ( logMAR , , OU) 
 
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018

Page 38of 59
 
 
.
Subjects will also be asked to complete the following series of questionnaires related to their 
lens wearing experiences with each stud y product :
Subjective ratings as related to  vision,
 
10.1 Informed Consent and Screening
The Investigator or delegate must explain the purpose and nature of the study , and have the 
subject read, sign, and date the I RB/IEC -approved informed consent document. The subject 
must sign the I CF BEFORE any  study -specific procedures or assessments can be performed, 
including study -specific screening procedures. Additionally , have the individual obtaining 
consent from the subject and a witness, if applicable, sign and date the informed consent 
document. 
The Investig ator or delegate must provide a cop y of the signed document to the subject and 
place the original signed document in the subject ’s chart, or provide documentation as 
required b y local regulations.
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018

Page 39of 59
10.2 Description of Study Procedures and Assessments
Detailed descriptions of assessments and procedures are provided in the MOP . The 
Investigator is responsible for ensuring responsibilities for all procedures and assessments are 
delegated to appropriately qualified site personnel.
10.2.1 Demographics
Obtain demographic in formation including age, race, ethnicity , and sex.
10.2.2 Medical History
Collect medical history  information , including information on all medications used within the 
past 30 days. Include herbal therapies, vitamins, and all over -the-counter as well as 
prescription medications. Throughout the subject’ s participation, obtain information on any  
changes in medical health and/or the use of concomitant medications.
10.2.3 Investigational Product compliance
Review subject compliance with the IP  usage and adjunct product usage and collect all used 
and unused study  IPs and other products that were dispensed.
10.2.4 Adverse Event Collection: Safety Assessment
Assess and record an y adverse events that are observed or reported, including those 
associated with changes in concomitant medication dosing since the previous visit.
10.2.5 Biomicr oscopy: Safety Assessment
SLE of the cornea, iris/anterior chamber and lens must be performed in both ey es before 
instillat ion of any  diagnostic ey e drops.
10.2.6 Device Deficiencies: Safety Assessment
Assess and record an y Device Deficiencies that are reported or observed since the previous 
visit. Requirements for reporting device deficiencies in the study  can be found in Section 1 1. 
 
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018

Page 40of 59
 
 
10.3 Unscheduled Visits
If a subject visit occurs between any  regularl y scheduled visits ,this visit must be documented 
as an Unscheduled V isit. During all unscheduled visits, the I nvestigator must conduct the 
following procedure s: 
Collect Adverse Event information
Record changes in medical condition or concomitant medication
Biomicroscop y
The Investigator may  perform additional procedures for proper diagnosis and treatment of the 
subject. The Investigato r must document this information in the subject’ s case history  source 
documents.
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018

Page 41of 59
If during an Unscheduled V isit the subject is discontinuing the IP or discontinuing from the 
study , the Investigator must conduct Earl y Exit procedures according to Table 3-1Schedule 
of Study  Procedures and 
Assessments and Section 10. 4.3, as possible.
10.4 Discontinued Subjects
10.4.1 Screen Failures
Subjects who were excluded from the stud y after signing the informed consent, not meeting 
inclusion/exclusion criteria, and prior to random ization to product/dispense (exposure) of 
study  product will be considered a screen failure .
The Investigator must document the reason for screen failure in the subject ’s case history  
source documents.
Subject numbers must not be re -used.
10.4.2 Discontinuations
Discontinued subjects are individuals who voluntarily
 withdraw or are withdrawn from the 
study  by the Investigator after signing the informed consent, including screen failures.
Subject numbers of discontinued subjects must not be re -used.
Subjects may  discontinue from study  or study  treatment at any  time for an y reason. Subjects 
may also be discontinued from study  treatment at any  time if, in the opinion of the 
Investigator , continued treatment poses a risk to their health.
For subjects discontinuing from the study , the Investigator must complete all Early Exit 
procedures according to T able 3 -1, Schedule of Study  Procedures and Assessments, if the 
subject is willing and able, and if, in the opinion of the Investigator it is safe for the subject to 
do so.
The Investigator must document the reason for study  or treatment discontinuation in the 
subject ’s case history  source documents.
To ensure the safet y of all subjects who discontinue earl y, Investigators must assess each 
subject and, if necessary , advise them of an y therapies and/or medical procedures that may  be 
needed to maintain their health.
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018
Page 42of 59
10.4.3 Schedule of Pr ocedures and Assessments for Subjects Discontinued 
from Investigational Product 
Other than screen failures, if a subject discontinues from the study  thesubject should undergo 
an Earl y Exit Visit. Refer to T able 3 -1, Schedule of Study  Procedures and assessments.
10.5 Clinical Study Termination
The Study  Sponsor reserves the right to close the investigational site or terminate the study  in 
its entirety  at any  time.
If the clinical stud y is prematurely terminated or suspended b y the Study Sponsor: 
The Study  Sponsor must:
oImmediately  notify  the Investigator(s) and subsequently  provide 
instructions for study  termination.
oInform the Investigator and the regulatory  authorities of the 
termination/suspension and the reason(s) for the termination/suspension. 
The Investigator must:
oPromptly  notify  the IRB/IEC of the termination or suspension and of the 
reasons.
oProvide subjects with recommendations for post- study  treatm ent options 
as needed.
The Investigator may  terminate the site ’s participation in the study  for reasonable cause.
10.5.1 Follow -up of subjects after study participation has ended
Following this study , the subject will return to their ey e care professional for the ir routine ey e 
care.
11ADVERSE EVENTS AND DEVICE DEFICIENCIES
11.1 General Information
An AE is an y untoward medical occurrence, unintended disease or injury , or untoward 
clinical signs (including abnormal laboratory  findings) in subjects, users, or other persons, 
whether or not related to the investigational medical device (test article). Refer to the 
Glossary  of Terms and figures below for categories of AEs and SAEs.
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018
Page 43of 59
Figur e11–1 Categorization of All Adverse Events
Figur e11-2 Categorization of All Serious Adverse
Specific Events Relevant to this Pr otocol
Serious Adverse Events
In addition to reporting all AEs (serious and non -serious) meeting the definitions, the 
Investigator must report any  occurrence of the following as an SAE:
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018
Page 44of 59
An ocular infection including a presumed infectious ulcer with an y of the following 
characteristics:
oCentral or paracentral location
oPenetration of Bowman ’s membrane
oInfiltrates > 2 mm diameter
oIritis
oIncrease in intraocular pressure
oCulture positive for microorganisms
oIncreasing size or severity  at subsequent timepoints
Any central or paracentral corneal event (such as neovascularizati on) that results in 
permanent opacification
Hypopy on
Hyphema
Neovascularization within the central 6 mm of the cornea
Permanent vision loss as defined b y loss of 2 or more lines of BCV A from enrollment 
that fails to resolve
Uveitis (anterior , intermediate, or posterior)
Corneal abrasion affecting ≥50% of corneal surface area
Significant Non -Serious Adverse Events
A significant non -serious AE is a device-related, non- sight threatening adverse event that 
warrants discontinuation of an y contact lens wear for greater than or equal to 2 weeks. In 
addition, the I nvestigator must report any  occurrence of the following as a Significant 
Non-Serious Adverse Event:
Peripheral non -progressive non- infectious ulcers
All sy mptomatic corneal infiltrative events
Corneal sta ining score greater than or equal to 
Grade 3 (Refer to MOP  for grading 
scales)
Temporary  vision loss as defined by  loss of 2 or more lines of BCV A from enrollment 
that persists for 2 or more weeks
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018
Page 45of 59
Neovascularization score greater than or equal to G rade 2 ( Refer to MOP for grading 
scales)
The above events are based upon the categories provided in the I SO 1 1980 and the US FDA  
Premarket Notification (510(k)) Guidance Document for Dail y Wear Contact Lenses
.
Device Deficiencies
A device deficiency  is inadequacy  of a medical device with respect to its identity , quality , 
durability , reliability , safety , or performance. A device deficiency  may  or may  not be 
associated with patient harm (ie, ADE or SADE); however , not all ADEs or SADEs are due 
to a device deficiency .The Investigator should determine the applicable category  listed in the 
Device Deficiency  eCRF for the identified or suspect device deficiency  and report an y patient 
harm separately . Examples of device deficiencies include the following: 
Failure to meet product specifications (eg, incorrect lens power/diameter/base 
curve/color)
Lens/solution cloud y
Lens surface/e dge defect
Torn lens during handling/in pack
Packaging deficit (eg, mislabeled product, tampered seal, leaking bottle/container)
Suspect product contamination
Lack of performance
11.2 Monitoring for Adverse Events
At the study  visit, after the subject has had the opportunity  to spontaneousl y mention any 
problems, the Investigator should inquire about 
AEs by asking the standard questions:
“Have you had a ny health problems since enrolling in the study ?”
“Have there been any  changes in the medicines you take since enrolling in the study ?”
Changes in any pr otocol -specific parameters and/or questionnair es evaluated during the 
study  are to be reviewed by  the I nvestigator . Any untoward (unfavorable and unintended) 
change in a pr otocol -specific parameter or questionnair e response that is clinically  relevant, 
in the opinion of the I nvestigator , is to be reported as an AE. These clinically  relevant 
changes will be reported regardless of causality .
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018
Page 46of 59
11.3 Procedures for Recording and Reporting
AEs are collected from the time of informed consent Any pre -existing medical conditions or 
signs/sy mptoms present in a subject prior to the start of the study  (ie, before informed 
consent is signed) are not considered AEs in the study  and should be recorded in the Medical 
History  section of the eCRF .
In addition, temporary  lens awareness or visual changes during the fitting process are not 
considered AEs if the Investigator assesses that the sy mptom(s) can reasonably  resolve within 
the anticipated adaptation period.
For each recorded event, the ADEs and SAEs documentation must include: date of 
occurrence, severity , treatment (if applicable), outcome, and assessments of the seriousness 
and causality . In addition, the I nvestigator must document all device deficiencies reported or 
observed with test and control articles on the Device Deficiency eCRF . The site must submit 
all available information on 
ADEs, SAEs, and device defic iencies to the Study  Sponsor 
immediately  as follows:
ADEs or SAEs are documented on the Serious Adverse Event and Adverse Device 
Effect eCRF within 24 hours of the Investigator ’s or site ’s awareness . 
Device deficiencies are documented on the Device Defici ency eCRF within 24 hours 
of the Investigator ’s or site ’s awareness . 
A printed cop y of the completed Serious Adverse Event and Adverse Device Effect 
and/or Device Deficiency eCRF must be included with product returns.
Additional relevant information after initial reporting must be entered into the eCRF as 
soon as the data become available.
Document an y changes to concomitant medications on the appropriate eCRFs.
Document all relevant information from Discharge Summary , Autopsy  Report,
Certificate of Death ,etc, if applicable, in narrative section of the Serious Adverse 
Event and Adverse Device Effect eCRF .
Note: Should the EDC system become non -
operational, the site must complete the 
appropriate paper Serious Adverse Event and Adverse Device Effect and/or Device Deficiency
Form. The completed form is emailed to the Study Sponsor to msus.safety@alcon.com
according to the timelines outlined above; however , the reported information must be entered 
into the EDC sy stem once it becomes operational.
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018
Page 47of 59
Study  Sponsor representatives may  be contacted for any  protocol related question and their 
contact information is provided in the Manual of Procedures that accompanies this protocol.
Further , depending upon the nature of the AE or device deficiency  being reported, the S tudy 
Sponsor may  request copies of applicable portions of the subject’ s medical records. The 
Investigator must also report all AEs and device deficiencies that could have led to a SADE 
according to the requirements of regulatory  authorities or I RB/IEC.
Intensity and Causality Assessments
Where appropriate, the Investigator must assess the intensity  (severit y) of the AE based upon 
medical judgment with consideration of an y subjective symptom(s), as defined below:
Intensity (Severity)
Mild An AE is mild if th
e subject is aware of but can easily  tolerate the sign or 
symptom.
Moderate An AE is moderate if the sign or s ymptom results in discomfort significant 
enough to cause interference with the subject ’s usual activities.
Severe An AE is severe if the sign or s ymptom is incapacitating and results in the 
subject ’s inability  to work or engage in their usual activities.
For every  AE in the study , the Investigator must assess the causalit y (Related or Not Related 
to the medical device or study  procedure). An assessm ent of causality  will also be performed 
by Study  Sponsor utilizing the same definitions, as shown below:
Causality
Related An AE classified as related may  be either definitely  related or possibl y related 
where a direct cause and ef fect relationship with th e medical device or study 
procedure has not been demonstrated, but there is a reasonable possibility  that 
the AE was caused by  the medical device or stud y procedure.
Not Related An AE classified as not related may  either be definitely  unrelated or simply  
unlikely  to be related (ie, there are other more likely  causes for the AE).
The Study  Sponsor will assess the A
Es and may  upgrade the Investigator ’s assessment of 
seriousness and/or causality . The Study  Sponsor will notify  the Investigator of an y AEs that i s 
upgraded from non -serious to serious or from unrelated to related .
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018
Page 48of 59
11.4 Return product analysi s
Study  Sponsor representatives and their contact information are provided in the MOP  that 
accompanies this protocol.
When study  products include Alcon marketed products (ie, DACP) such products associated 
with device deficiencies and/or product related AEs [ie, ADE or SADE] should be returned 
and must include the Complaint # which will be provided b y Study Sponsor after the case is 
entered in the Stud y Sponsor’s Glob al Product Complaint Management Sy stem, as 
applicable. These products should be returned to the Sponsor at the end of the study , unless 
instructed otherwise b y the Sponsor. Investigational product (ie, DACP Digital) associated 
with device deficiencies and/or product related AEs [ie, ADE or SADE] will also be returned 
for investigation as detailed in the MOP.
11.5 Unmask ing of the Study Treatment
Masked information on the identity  of the assigned 
study  product should not be disclosed 
during the stud y (See Section 9.4). I f the treatment code needs to be broken in the interest of 
subject safet y, the Investigator is encouraged to contact an appropriate Study  Sponsor 
representative prior to unmasking the informatio n if there is suf ficient time. Dependent upon 
the individual circumstances (ie, medical emergency), the code may be broken prior to 
contact with the Study  Sponsor . The Stud y Sponsor must be informed of all cases in which 
the code was broken and of the circ umstances involved. Additionally , the Study  Sponsor may  
be required to unmask the information in order to fulfill expedited regulatory reporting 
requirements.
11.6 Follow -Up of Subjects with Adverse Events
The Investigator is responsible for adequate and safe medical care of subjects during the 
study  and for ensuring that appropriate medical care and relevant follow -up procedures are 
maintained after the study . 
The Investigator should provide the Study  Sponsor with any  new safet y information (which 
includes ne w AEs and changes to previousl y reported AEs) that may  affect the safet y 
evaluation of the device. For AEs that are unresolved/ ongoing at time of subject exit from 
study , any  additional information received at follow -up should be documented in the eCRFs 
up to study  completion (ie, database lock). 
Any additional data received up to 1month after subject discontinuation or exit must be 
documented and available upon the Study  Sponsor ’s request. All complaints received after 
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018
Page 49of 59
this time period will be considere d and processed as spontaneous (following the post- market 
vigilance procedures) and should be communicated to the medical device ’s manufacturer as 
per local requirements.
The Investigator should alsoreport complaints on non -Alcon products directly  to the 
manufacturer as per the manufacturer ’s instructions or local regulatory  requirements.
11.7 Pregnancy in the Clinical Study
Women who are pregnant at the time of study  entry  are excluded from participation. If any 
pregnancy  is reported during the study , it should be included in the Medical History  section 
of the eCRF . Pregnancy  is not reportable as an AE; however , complications may  be 
reportable and will be decided on a case –by-case basis .
12
ANAL YSIS PLAN
Continuous variables will be summarized using the number of observations, mean, standard 
deviation (SD), median, minimum and maximum, as well as confidence intervals (CI s) or 
confidence limits where applicable. Categorical variables will be summarized with counts 
and percentages from each category .Any deviations t o the analysis plan will be updated 
during the course of the study  as part of a protocol amendment or will be detailed in the 
clinical study  report.
12.1 Subject Evaluability
Final subject evaluability must be determined prior to breaking the code for masked le ns 
sequence assignment and locking the database, based upon the Deviations and Evaluability  
Plan (DEP) .
12.2 Analysis Sets
12.2.1 Safety Analysis Set
Safety  anal yses will be conducted using the safet y anal ysis set on a treatment
-emergent basis.
As such, the safety  analysis set will include all subjects/eyes exposed to any stud y lenses
evaluated in this study . For treatment -emergent safety anal yses, subjects/eyes will be
categorized under the actual study  lenses exposed in the corresponding lens sequence.
12.2.2 Full Analysis Set
The full anal ysis set (F AS) is the set of all randomized subjects who are exposed to any  study
lenses evaluated in this study .
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018
Page 50of 59
12.2.3 Per Protocol Analysis Set
The per protocol (PP) analy sis set is a subset of FAS and excludes all data /subjects which 
have me tany of the critical deviation or evaluability  criteria identified in the DEP.
12.3 Demographic and Baseline Characteristics
Demographic and baseline characteristics will be summarized by  lens sequence and overall. 
Counts and percentages will be presented for categorical variables such as sex, age group, 
race, and ethnicity . Number of observations, mean, SD, median, minimum, and maximum 
will be presented for continuous variables such as age.
12.4 Effectiveness Analyses
This study  defines 1 primary , 1 secondary ,  effectiveness endpoints. 
All effectiveness evaluations will use the FAS as the primary  anal ysis set.  
 
 
12.4.1 Analysis of Primary Effectiveness Endpoint(s)
The primary  objective of this study  is to demonstrate noninferiorit y in Distance V A with 
DACP  Digital when compared to DACP  at the 1 -Week Follow -up V isit. The primary  
endpoint is distance V A with study  lenses, collected bilaterall y (OU) in logMAR .
12.4.1.1 Statistical Hypotheses
The null and alternative hy potheses are formulated in terms of the predefined margin of 0.05 
for noninferiority :
H0: μ(DACP D )- μ(DACP) ≥ 0.05
Ha: μ(DACP D) - μ(DACP) < 0.05
where μ (DACP D) and μ (DACP) denote the mean distance VA (in logMAR) for DACP Digital and 
DACP, respectivel y.
12.4.1.2 Analysis Methods
A mixed effect repeated measures model will be utilized to test these hypotheses. The model 
will include terms for lens, visit, lens by  visit interaction, period, and sequence. 
Within -subject correlation due to the crossover will also be accounted for in the model. Lens 
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018

Page 51of 59
difference (DACP Digital minus DACP) and the correspond ing one -sided 95% upper 
confidence limit will be computed at 1-W eek. Noninferiority  in VA will be declared if upper 
confidence limit is less than 0.05.
12.4.2 Analysis of Secondary Effectiveness Endpoints
The secondary  objective of this study  is to demonstrate no ninferiorit y in subjective overall 
vision with DACP  Digital when compared to DACP  at the 1- Week Follow-up V isit. The 
secondary  endpoint is the subjective rating of overall vision on a scale of 1 (Poor) to 
10(Excellent).
12.4.2.1 Statistical Hypotheses
The null and alternative hy potheses are formulated in terms of the predefined margin of 1.0
for noninferiority :
H0: μ(DACP D) - μ(DACP) ≤ -1.0
Ha: μ(DACP D) - μ(DACP) > -1.0
where μ(DACP D) and μ(DAC P)denote the mean overall vision rating for DACP  Digital and 
DACP , respectively .
12.4.2.2 Analysis Methods
A mixed ef fect repeated measures model will be utilized to test these hy potheses. The model 
will include terms for lens, period, and sequence. W ithin-subject correlation due to crossover 
will also be accounted for in the mode
l. Lens dif ference (DACP  Digital minus DACP) and 
the corresponding one -sided 95% lower confidence limit will be computed. Noninferiorit y in
overall vision will be declared if lower confidence limit is greater than -1.0.
 
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018

Page 52of 59
 
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018

Page 53of 59
 
12.5 Handling of Missing Data
All data obtained in evaluable subjects/ey es will be included in the analy sis. No imputation 
for m issing values will be carried out for the primary  and secondary  effectiveness anal yses.
12.6 Safety Analys es
The safet y endpoints are: 
AEs
Biomicroscop y finding s
Device deficiencies
There are no safet y hypotheses planned in this study . The focus of the safet y analysis will be 
a comprehensive descriptive assessment of occurrence of adverse events as well as the other 
listed parameters.
All AEs occurring from the time a subject signs informed consent to study  exit will be 
accounted for in the reporting. Safety  analyses will be conducted using the safet y analysis set 
on a treatment -emergent basis. Descriptive summaries (counts and percentages) for ocular 
and nonocular AEs will be presented by  Medical Dictionary  for Regulatory  Activities 
Preferred Terms. AEs leading to study  discontinuation, significant nonserious AEs, and SAEs 
will be identified. Individual subject listings will be provided, as necessary . 
Individual subject listings will be provided for AEs that occur after signing informed consent 
but prior to exp osure to IP .
Each biomicroscop y parameter will be tabulated by its grade. For each biomicroscop y 
parameter , counts and percentages of ey es that experience an increase of ≥ 2 grades from 
baseline (last assessment prior to study  lens exposure) to an y subsequ ent visit within the 
same period will be presented. A supportive listing will be generated which will include all 
biomicroscopy  data from all visits within the same period for those eyes experiencing the 
increase.
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018

Page 54of 59
Two listings for device deficiencies, prior to exposure of stud y lenses and 
treatment -emergent, will be provided. Additionally , each device deficiency  category  will be 
tabulated. 
No inferential testing will be done for safet y anal ysis.
 
12.8 Sample Size Justification
Sample size calculation is based on a prior clinical study  (M-14-010) which partly  evaluated 
performance of DAC P Multifocal and DACP lenses
.
To demonstrate noninferiority  (margin =0.05 logMAR) as a one -tailed hypothesis with 
α=0.05, and using a standard deviation of 0.098 for paired differences, 80% power can be 
attained with a sample size of 36 (18 per sequence g roup).
To demonstrate noninferiority  (margin =1.0) as a one -tailed hy pothesis with α=0.05, and 
using a standard deviation of 2.29 for paired dif ferences, 80% power can be attained with a 
sample size of 48 (24 per sequence group).
13DA TA HANDLING AND ADMINISTRA TIVE REQUIREMENTS
13.1 Subject C onfidentiality
The Investigator must ensure that the subject ’s anony mity is maintained throughout the 
course of the stud y. In particular , the Investigator must keep an enrollment log with 
confidential identify ing information that corresponds to the subject numbers and in itials of 
each stud y participant. At the end of the clinical study , the Study  Sponsor will collect a copy  
of the enrollment log without any identifying subject information . All documents submitted 
to the Study  Sponsor will identify  the subjects exclusively by number and demographic 
information. No other personally  identify ing information will be transmitted to the Study  
Sponsor .
The Study  Sponsor may  release anony mized study data to external researchers for purposes 
of future research directly  related to th e stud y objectives, or future research that is bey ond the 
scope of the current study objectives. The Informed Consent Form explains this to study  
subjects. Anon ymization means that all identifiable information will be removed from the 
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018

Page 55of 59
dataset and all links to the subjects in the study  will be removed. Anon ymization of the data 
will maintain confidentiality  of the subjects who participate in the study  so that they  cannot 
be identified b y external researchers. The anon ymized data set will contain records from all 
of the subjects in the current study , but the anonymization process might change the data set 
in some way s, so external researchers will be informed that they  might not be able to 
duplicate some o f the results from this study .
13.2 Completion of Sour ce Documents and Case Report Forms
The nature and location of all source documents will be identified to ensure that original data 
required to complete the CRFs exist and are accessible for verification by  the site monitor , 
and all discrepancies shall be appropr iately  documented via the query  resolution process. Site
monitors are appointed by the Stud y Sponsor and are independent of stud y site staf f.
If electronic records are maintained, the method of verification must be determined in
advance of starting the study . 
At a minimum, source documents include the following information for each subject:
Subject identification (name, sex, race/ethnicit y)
Documentation of subject eligibility
Date of informed consent
Dates of visits
Documentation that protocol specific pr ocedures were performed
Results of study  parameters, as required b y the protocol
IP accountability  records
Documentation of AEs and other safet y parameters (if applicable)
Records regarding medical histories and the use of concomitant therapies prior to an d 
during the stud y
Date of stud y completion and reason for earl y discontinuation, if applicable
It is required that the author of an entry  in the source documents be identifiable. Direct access 
to source documentation (medical records) must be allowed for the purpose of verify ing that 
the data recorded on the CRF are consistent with the original source data.
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018
Page 56of 59
Only  designated individuals at the site will complete the CRFs. The CRFs must be completed 
at regular intervals following the clinical study  visit sche dule. I t is expected that all data 
reported have corresponding entries in the source documents. The Principal I nvestigator is 
responsible for reviewing and certify ing that the CRFs are accurate and complete. The onl y 
subject identifiers recorded on the CRF s will be subject number , and subject demographic 
information. 
13.3 Data Review and Clarifications
A review of CRF data to the subject’ s source data will be completed by  the site monitor to 
ensure completeness and accuracy . After the CRFs have been completed, additional data 
clarifications and/or additions may  be needed as a result of the data cleaning process. Data 
clarifications are documented and are part of each subject’ s CRF .
13.4 Sponsor and Monitoring Responsibilities
The Study  Sponsor will designate a monito r to conduct the appropriate site visits at the 
appropriate intervals according to the stud y monitoring plan. The clinical investigation will 
be monitored to ensure that the rights and well -being of the subjects are protected, the 
reported data are accurate, complete, and verifiable from the source documents, and the study  
is conducted in compliance with the current approved protocol (and amendments[s], if 
applicable), with current GCP , and with applicable regulatory  requirements.
The site may  not screen subjects or perform the informed consent process on any  subject until 
it receive sa notification from an appropriate Study Sponsor representative that the site may  
commence conducting study  activities . Monitoring will be conducted periodically  while the 
clin
ical study  is ongoing. Monitoring methods may  include site visits, telephone, written and 
fax correspondence. Close -out visits will take place after the last visit of the last subject at the 
site.
A Coordinating Investigator may  be identified by  the Study  Sponsor to review and endorse 
the final study  report. In cases where a Coordinating Investigator is engaged , the Study  
Sponsor will select the Coordinating Investigator based upon their experience, qualifications, 
active study  participation, and their will ingness and ava ilability  to take on this role.
13.5 Regulatory Documentation and Records Retention
The Investigator is required to maintain up- to-date, complete regulatory  documentation as 
indicated b y the Study Sponsor and the Investigator ’s files will be reviewed as part of the 
ongoing stud y monitoring. Financial information is to be kept separately . 
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018
Page 57of 59
Additionally , the Investigator must keep study records and source documents consistent with 
the terms of the clinical study  agreement with the Study  Sponsor . If the Investigator retires, 
relocates, or for an y other reason withdraws from responsibility  of keeping the study  records, 
then the Study  Sponsor must be notified and suitable arrangements made for retention of 
study  records and source documents needed to comply  with national and international 
regulations.
13.6 Quality Assurance and Quality Contr ol
The St udy Sponsor will secure agreement from all involved parties to ensure direct access to 
all study  related sites, source data and documents, and reports for the purpose of monitoring 
and auditing b y the Study Sponsor , and inspection by  domestic and foreign r egulatory  
authorities. Quality  control will be applied to each stage of data handling to ensure that all 
data are reliable and have been processed correctly . Agreements made b y the Study  Sponsor 
with the I nvestigator/Institution and any other parties invol ved in the clinical study  will be 
provided in writing as part of the protocol or as a separate agreement.
14ETHICS
This clinical study  must be conducted in accordance with the ethical principles contained 
within: 
The D eclaration of Helsinki , and in complian ce with the I CH E6 GCP  Consolidated 
Guideline, I SO14155:201 1, and the applicable US FDA  21 CFR Regulations. 
SOPs of the Study  Sponsor and contract research organizations participating in the 
conduct of the clinical study  and all other applicable regulations. 
Notifications and timelines for reporting protocol deviations should be based upon
applicable Ethics Committee requirements
The Investigator must ensure that all personnel involved in the conduct of the study  are 
qualified to perform their assigned r esponsibilities through relevant education, training, and 
experience. The Investigator and all clinical stud y staf f must conduct the clinical study  in 
compliance with the protocol. Deviations from this protocol, regulatory  requirements and/or 
GCP  must be r ecorded and reported to the Sponsor prior to database lock. If needed, 
corrective and preventive action should be identified, implemented, and documented within 
the study  records. Use of waivers to deviate from the c linical protocol is prohibited.
Before c linical study  initiation, this protocol, the informed consent form, any  other written 
information given to subjects, and an y advertisements planned for subject recruitment must 
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018
Page 58of 59
be approved b y an IRB/IEC. The Investigator must provide documentation of the I RB/IEC 
approval to the Study  Sponsor . The approval must be dated and must identify the applicable 
protocol, amendments (if any ), informed consent form, assent form (if any ), all applicable 
recruiting materials, written information for subject, and subject compensation programs. The 
IRB/IEC must be provided with a cop y of the Clinical IB , package insert of DACP , any  
periodic safety  updates, and all other information as required by  local regulation and/or the 
IRB/IEC. At the end of the study , the Investigator must notify  the IRB/IEC about the study ’s 
completion. The IRB/IE C also must be notified if the study  is terminated prematurel y. 
Finally , the Investigator must report to the I RB/IEC on the progress of the study  at intervals 
stipulated by  the IRB/IEC.
Voluntary informed consent must be obtained in writing from every
 subject and the process 
shall be documented before an y procedure specific to the clinical investigation is applied to 
the subject. The Investigator must have a defined process for obtaining conse nt. Specifically , 
the Investigator , or their delegate, must explain the clinical study  to each potential subject and 
the subject must indicate voluntary  consent by  signing and dating the approved informed 
consent form. The subject must be provided an oppor tunity  to ask questions of the 
Investigator , and if required by  local regulation, other qualified personnel. The Investigator 
must provide the subject with a cop y of the consent form written in a language the subject 
understands. The consent document must meet all applicable local laws and provide subjects 
with information regarding the purpose, procedures, requirements, and restrictions of the 
study , along with any  known risks and potential benefits associated with the IP  and the study , 
the available compe nsation, and the established provisions for maintaining confidentiality  of 
personal, protected health information. Subjects will be told about the voluntary  nature of 
participation in the study  and must be provided with contact information for the appropri ate 
individuals should questions or concerns arise during the study . The subject also must be told 
that their records may  be accessed b y appropriate authorities and Sponsor -designated 
personnel. The Investigator must keep the original, signed cop y of the c onsent (file in 
subject ’s medical records ) and must provide a duplicate cop y to each subject according to 
local regulations. 
The Study  Sponsor assures that the key  design elements of this protocol will be registered on 
www .clinicaltrials.gov as required b y current regulations and, if applicable, other public 
databases as required b y local country  regulations. I n addition, results of this study  will be 
made publicly  available on www .clinicaltrials.gov regardless of outcome as required b y 
current regulations and, if applicable, in other public databases as required by  local country  
regulations.
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018
Page 59of 59
15REFERENCES
15.1 References applicable for all clinical studies
ISO 1 1980:2012 Ophthalmic optics -Contact lenses and contact lens care products -
Guidance for clinical inve stigations
ISO 14155:201 1 Clinical investigation of medical devices for human subjects -Good 
clinical practice
15.1.1 US references applicable for clinical studies
21 CFR Part 1 1 -Electronic Records; Electronic Signatures
21 CFR Part 50 
-Protection of Human Subjects
21 CFR Part 56 - Institutional Review Boards
21 CFR Part 812 - Investigational Device Exemptions
21 CFR Part 54 - Financial Disclosure b y Clinical Investigators
The California Bill of Rights
15.2 References for this clinical study
Not applicable. There are no references .
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018
                                                                                                                
                                                                                     
Date/Time 
(mm/dd/yyyy GMT): Signed by: Justification :
biostatistics
Global Device Medical Safety
Global Device Medical Safety
Clinical Project Lead & SME
07/16/2018 20:49:20
07/16/2018 19:00:03
07/14/2018 03:58:10
07/14/2018 03:58:10
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0055077
Protocol - Clinical
16-Jul-2018
